Founders and Directors

HasenTech’s founders have a long history of collaboration in the field of translational immunology. Their partnership includes the formation of Hematech, a biotech company co-founded by Drs. Goldsby and Osborne in 1999, and in which Dr. Knight served as a member of the Scientific Advisory Board. Hematech was sold to Kirin Pharma in 2005, a testament to their expertise, strong working relationship, and success in creating and scaling innovative therapies from discovery to commercialization.​

Katherine L. Knight, PhD

​CO-FOUNDER

Professor and Chair Department of Microbiology & immunology Loyola University Chicago

Pioneered rabbit monoclonal antibody technology

Discovered anti-inflammatory properties of EPS
​
Past President of American Association of Immunologists (AAI) 
​

MORE INFO

Barbara A. Osborne, PhD

​CO-FOUNDER

Distinguished University Professor Department of Veterinary & Animal Sciences, UMass Amherst

Contributions to T Cell signaling & Cell Death
​
Fellow National Academy of Inventors

Co-Founder Hematech (now Sanford Biotherapeutics)

MORE INFO

Richard A Goldsby, PhD

​CO-FOUNDER

Formerly Professor of Veterinary & Animal Sciences, UMass Amherst & Cross Professor of Biology, Amherst College

Extension of monoclonal antibody technologies to animals & applications of veterinary interest
​
Co-Founder Hematech (now Sanford Biotherapeutics)

​

MORE INFO

Lisa M. Minter, PhD

MEMBER, BOARD OF DIRECTORS​

Professor & Department Head, Veterinary & Animal Science UMass Amherst

Immunologist & Leader in field of bone marrow failure
​
Consultant 




​

More Info

Patrick J. Stiff, MD

MEMBER, BOARD OF DIRECTORS​

Clinical Professor, Loyola University (Chicago) School of Medicine

Former Director of Cardinal Bernardin Cancer Center at Loyola (Chicago) Medical Center
​
Service on SAB of SWOG (Southwest Oncology Group, an NCI supported organization that conducts clinical trials)